Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Taxes (2016 - 2025)

Ani Pharmaceuticals' Change in Taxes history spans 12 years, with the latest figure at $472000.0 for Q4 2025.

  • For Q4 2025, Change in Taxes fell 96.33% year-over-year to $472000.0; the TTM value through Dec 2025 reached -$15.5 million, down 997.6%, while the annual FY2025 figure was -$15.5 million, 997.6% down from the prior year.
  • Change in Taxes for Q4 2025 was $472000.0 at Ani Pharmaceuticals, up from -$12.5 million in the prior quarter.
  • Across five years, Change in Taxes topped out at $12.9 million in Q4 2024 and bottomed at -$14.3 million in Q2 2024.
  • The 5-year median for Change in Taxes is -$148000.0 (2021), against an average of -$634400.0.
  • The largest annual shift saw Change in Taxes soared 15538.78% in 2023 before it tumbled 3942.21% in 2024.
  • A 5-year view of Change in Taxes shows it stood at -$637000.0 in 2021, then surged by 92.31% to -$49000.0 in 2022, then skyrocketed by 15538.78% to $7.6 million in 2023, then surged by 69.9% to $12.9 million in 2024, then plummeted by 96.33% to $472000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Change in Taxes are $472000.0 (Q4 2025), -$12.5 million (Q3 2025), and -$10.9 million (Q2 2025).